NYSEMKT: RVPRetractable Technologies Inc Stock
$0.74-0.01 (-1.33%)
Updated Mar 27, 2025
RVP Price
$0.74
Fair Value Price
N/A
Market Cap
$22.06M
52 Week Low
$0.57
52 Week High
$1.22
P/E
-1.36x
P/B
0.26x
P/S
0.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$38.27M
Earnings
-$15.73M
Gross Margin
7.9%
Operating Margin
-18.83%
Profit Margin
-41.7%
Debt to Equity
0.89
Operating Cash Flow
-$9M
Beta
1.12
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RVP Overview
Retractable Technologies, Inc. manufactures and markets safety needle devices for the healthcare industry. The company is headquartered in Little Elm, Texas and currently employs 134 full-time employees. The firm markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. The company also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RVP's potential to beat the market
- RVP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
RVP
RankedUnranked of 43
RankedUnranked of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $49.98 | B | |
| $103.27 | B | |
| $6.06 | B |
Be the first to know about important RVP news, forecast changes, insider trades & much more!
RVP News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RVP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RVP is good value based on its book value relative to its share price (0.26x), compared to the US Medical Instruments & Supplies industry average (3.8x)
P/B vs Industry Valuation
RVP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RVP due diligence checks available for Premium users.
Valuation
RVP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.36x
Industry
42.1x
Market
31.08x
RVP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
3.8x
RVP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVP's financial health
Profit margin
Revenue
$10.3M
Net Income
-$1.9M
Profit Margin
-19.1%
RVP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RVP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$157.8M
Liabilities
$74.4M
Debt to equity
0.89
RVP's short-term assets ($68.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVP's short-term assets ($68.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RVP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
$2.9M
Financing
-$134.3k
RVP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RVP vs Medical Stocks
Retractable Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.